drugset / Trial / NCT02833415

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

NCT02833415

RandomizedParallel-groupDouble-blindPrevention

Summary

This study is a clinical study to investigate the gluconeogenesis pathway related to visceral adipose tissue (VAT) in obese individuals without type 2 diabetes and the effects of empagliflozin (EMPA) on glucose homeostasis in viscerally-obese individuals using functional studies of glycerol metabolism in hepatic gluconeogenesis using a well-validated nuclear magnetic resonance (NMR) spectroscopy platform.

Timeline

Start
2016-03
Primary completion
2018-01
Completion
2018-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg
Subject Glycerin Other / unclassified 50 mg/kg Oral

Indications